JERUSALEM, March 15, 2021 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") announced today that it has entered into a definitive agreement for a business combination with ...

"We entered 2020 with a focused agenda for leveraging our Accordion Pill platform in both the near- and long-term, with goals to outlicence our late-stage Parkinson's disease program, to advance our ...

WeissLaw LLP is investigating whether Intec’s board acted in the best interest of Intec’s public shareholders in agreeing to the proposed transaction, whether the board was fully informed as to the ...

TEL AVIV (Reuters) - Israel's Intec Pharma, which is conducting a late stage trial for its long-lasting pill to treat Parkinson's disease, expects to start earning money from the program sometime in ...

JERUSALEM, Oct. 29, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces a 1-for-20 reverse share split of its outstanding ordinary shares. The reverse ...

Intec Pharma, the maker of the Accordion delivery platform, is partnering with LTS Lohmann Therapie-Systeme of Germany to manufacture its lead drug candidate Accordion Pill carbidopa/levodopa, ...